Abstract:Objective: To study the expression of α5β1 integrin and phosphorylated ERK1/2(p-ERK1/2) in non-small cell lung cancer (NSCLC), and the effect of α5β1 integrin and ERK signal transduction pathway on proliferation and migration of A549 cells. Method: The expression of α5β1 integrin and p-ERK1/2 in 41 specimens of NSCLC, and 15 controled specimens were determined by immunohistochemical assay and Western blot analysis. The correlation between the results of two methods was then analyzed. A549 cells were cultured in vitro, with anti-α5β1 and ERK. inhibitor PD98059 as the tool drugs. The proliferation and apoptosis of the A549 cells were measured with the MTT assay and Annexin-V FITC PI double staining, respectively. The protein expression level of MMP-9 was measured with Western blot analysis. The protein expression levels of ERK1/2 were detected by Western blot analysis and the expression levels of ERK1/2 mRNA was measured by RT-PCR. Result: The expression of α5β1 integrin and p-ERK1/2 was significantly higher in NSCLC (58.53% and 65.52%, respectively) compared with that in the normal lung tissue (26.67% and 20.00% respectively). There was also a positive correlation of α5β1 integrin and p-ERK1/2 expression with pathological characteristics (P = 0.000, P = 0.030), lymph node metastasis (P = 0.014, P = 0.000), and clinical stage (P = 0.027, P = 0.038). The expression of α5β1 integrin was positively correlated with p-ERK1/2 expression (r = 0.375, P < 0.05). The anti-α5β1 and ERK inhibitor PD98059 could inhibit the proliferation of A549 cells, resulting in an increase of the percentage in the early apoptotic cells, and down-regulated the expression of MMP-9. In addition, the anti-α5β1 could inhibit the phosphorylated ratio of ERK by down-regulating the expression of ERK mRNA and the relative proteins. Conclusion: The positive rates of α5β1 integrin and p-ERK1/2 are higher in NSCLC than in the normal lung tissue. Anti-α5β1 can down-regulate the expression of ERK mRNA and the phosphorylated ratio, and can inhibit the proliferation of A549 cells and down-regulate the expression of MMP-9. This indicates that the α5β1 integrin-mediated ERK signal transduction pathway might lead to the abnormal proliferation and migration of A549 cells.

[PHF5A Promotes Proliferation and Migration of Non-Small Cell Lung Cancer by Regulating of PI3K/AKT Pathway].

PHD-finger Domain Protein 5A Functions As a Novel Oncoprotein in Lung Adenocarcinoma

Knockdown of PHF5A Inhibits Migration and Invasion of HCC Cells Via Downregulating NF-κB Signaling

PPIP5K2 Facilitates Proliferation and Metastasis of Non-Small Lung Cancer (NSCLC) through AKT Signaling Pathway

PHF12 regulates HDAC1 to promote tumorigenesis via EGFR/AKT signaling pathway in non-small cell lung cancer

CXCL5 Regulation of Proliferation and Migration in Human Non-Small Cell Lung Cancer Cells

Inhibition of protein phosphatase 5 suppresses non-small cell lung cancer through AMP-activated kinase activation

SLC39A5 Promotes Lung Adenocarcinoma Cell Proliferation by Activating PI3K/AKT Signaling

Effect of α5β1 Integrin and ERK Signaling Pathway on Non-small Cell Lung Cancer

High Expression of WNT5A in Small Cell Lung Cancer and Promotion of Cell Migration by Phosphorylation of JNK

Comprehensive analysis of PHF5A as a potential prognostic biomarker and therapeutic target across cancers and in hepatocellular carcinoma

PRC1 Promotes Cell Proliferation and Cell Cycle Progression by Regulating P21/p27-Prb Family Molecules and FAK-paxillin Pathway in Non-Small Cell Lung Cancer.

SNF5 Promotes Cell Proliferation and Immune Evasion in Non-Small Cell Lung Cancer

Fibroblast activation protein-α promotes the growth and migration of lung cancer cells via the PI3K and sonic hedgehog pathways

UNC5A, an epigenetically silenced gene, functions as a tumor suppressor in non-small cell lung cancer

CHD4 Mediates Proliferation and Migration of Non-Small Cell Lung Cancer Via the RhoA/ROCK Pathway by Regulating PHF5A

The effect of Phosphoinositide-3-kinase, regulatory subunit 3 in epithelial-mesenchymal transition and migration of non-small cell lung cancer

NLR family CARD domain containing 5 promotes hypoxia-induced cancer progress and carboplatin resistance by activating PI3K/AKT via carcinoembryonic antigen related cell adhesion molecule 1 in non-small cell lung cancer

PHF5A regulates the expression of the DOCK5 variant to promote HNSCC progression through p38 MAPK activation

PHF5A Epigenetically Inhibits Apoptosis to Promote Breast Cancer Progression

PHLDA3 promotes lung adenocarcinoma cell proliferation and invasion via activation of the Wnt signaling pathway